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Background: Many advanced human tumors, including hepatocellular carcinomas (HCC) are auxotrophic for
arginine due to down-regulation of argininosuccinate synthetase (ASS1), the rate-limiting enzyme in arginine
synthesis. The arginine-lowering agent PEGylated arginine deiminase (ADI-PEG 20) has shown efficacy as a
monotherapy in clinical trials for treating arginine-auxotrophic tumors and is currently being evaluated in
combination with cisplatin in other cancer types. Epigenetic silencing via methylation of the ASS1 promoter has
been previously demonstrated in other cancer types, and a reciprocal relationship between ASS1 expression and
cisplatin resistance has also been observed in ovarian cancer. However, the mechanism of ASS1 down-regulation, as
well as the correlation with cisplatin resistance has not been explored in HCC. The present study investigates
ADI-PEG 20 and cisplatin sensitivities in relation to ASS1 expression in HCC. In addition, we show how this
biomarker is regulated by cisplatin alone and in combination with ADI-PEG 20.
Methods: ASS1 protein expression in both untreated and drug treated human HCC cell lines was assessed by
western blot. The correlation between ASS1 protein levels, ADI-PEG 20 sensitivity and cisplatin resistance in these
cell lines was established using a luminescence-based cell viability assay. Epigenetic regulation of ASS1 was
analyzed by bisulfite conversion and methylation-specific PCR.
Results: A good correlation between absence of ASS1 protein expression, ASS1 promoter methylation, sensitivity
to ADI-PEG 20 and resistance to cisplatin in HCC cell lines was observed. In addition, cisplatin treatment
down-regulated ASS1 protein expression in select HCC cell lines. While, at clinically relevant concentrations, the
combination of ADI-PEG 20 and cisplatin restored ASS1 protein levels in most of the cell lines studied.
Conclusion: ASS1 silencing in HCC cell lines is associated with simultaneous cisplatin resistance and ADI-PEG 20
sensitivity which suggests a promising combination therapeutic strategy for the management of HCC.
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Arginine, a semi-essential amino acid in humans, is crit-
ical for the growth of human cancers [1]. Tumoral
down-regulation of the enzyme argininosuccinate syn-
thetase (ASS1), the rate-limiting step in arginine syn-
thesis, results in a critical dependence on extracellular
arginine due to an inability to synthesize this amino acid
from citrulline. Such a dependence on extracellular ar-
ginine is known as arginine auxotrophy. Many advanced
human tumors more commonly associated with che-
moresistance and poor clinical outcome, including hepa-
tocellular carcinoma (HCC), melanoma, mesothelioma,
pancreatic cancer, prostate cancer, renal cell carcinoma,
sarcoma and small cell lung cancer, exhibit loss of ASS1
expression and are thus arginine auxotrophs [2-9]. Con-
versely, other tumor types such as colorectal, gastric and
ovarian cancer tend to have higher expression of ASS1
[10,11]. The mycoplasma-derived enzyme, arginine dei-
minase (ADI-PEG 20), PEGylated to enhance bioavail-
ability and reduce immunogenicity, selectively degrades
arginine, resulting in cell death in tumors lacking ASS1
[12]. Several phase I/II clinical trials of ADI-PEG 20 in
patients with HCC and metastatic melanoma have
shown promising indication of clinical benefit and low
toxicity in patients with ASS1-deficient tumors [13-18].
A recently completed phase II trial of single-agent ADI-
PEG 20 in ASS1-negative patients with mesothelioma
also revealed encouraging efficacy results [19,20].
The significance for ASS1 loss in cancer is currently un-
clear; however, several groups have revealed that reduced
expression of ASS1 is a predictive biomarker for the deve-
lopment of metastasis and is associated with a worse clini-
cal outcome [21-25]. Epigenetic silencing via methylation
of the CpG islands within the ASS1 promoter accounts
for loss of ASS1 expression in many solid tumors studied
to date, including ovarian, malignant pleural mesothe-
lioma, glioblastoma, myxofibrosarcoma and bladder, as
well as in some lymphoid malignancies [4,22-24,26,27].
Interestingly, the methylation status of ASS1 has been
linked to platinum resistance in ovarian cancer [22]. Fur-
thermore, it was found that patients treated with first line
platinum/paclitaxel for ovarian cancer had a poor overall
and disease-free survival if the tumor exhibited methylated
ASS1 compared to unmethylated ASS1 [22,28]. In ad-
dition, methylated ASS1 has been linked to increased pro-
liferation and invasion of bladder cancer cells [24].
HCC is one of the most common cancers in the world,
especially in Asia and Africa [29]. Cisplatin has been
commonly used as a chemotherapeutic agent for HCC,
but it has not satisfactorily improved the survival rate
for patients with advanced HCC, either as a single agent
or in combination, due to acquired or intrinsic drug re-
sistance [30]. Intriguingly, drug resistance is an impor-
tant contributor for treatment failure of ASS1-negativetumors by ADI-PEG 20, possibly due to re-expression of
the once-silenced ASS1 that has been observed in me-
lanoma cell lines [31-33]. To overcome this type of resis-
tance, a second drug must be added to drive cell death.
For example, it has been observed that the combination
of ADI-PEG 20 and cisplatin can increase apoptosis in
melanoma cell lines [34]. In addition, combined treat-
ment of oxaliplatin and human arginase in HCC ex-
hibited synergistic inhibiting effect on tumor growth
[35], providing further support that a platinum and an
arginine-deprivation agent would be a good combination
in this cancer. ADI-PEG 20 is currently being utilized in
several clinical trials, including a global phase III trial for
HCC as a monotherapy, as well as in combination with
cytotoxics such as cisplatin for the treatment of mela-
noma and ovarian cancer.
Previous work has shown that the sensitivity of HCC
cell lines to ADI-PEG 20 is due to the absence of ASS1
[3]. However, the mechanism of ASS1 silencing, as well
as the correlation with platinum resistance has not been
explored in HCC. In addition, although ASS1 loss has
been identified as a potential indicator of arginine auxot-
rophy in cancer, its regulation is complex and its use as
a biomarker in combination therapy is unfamiliar. The
current investigation was initiated to elucidate the rela-
tionship between ASS1 protein expression, ADI-PEG 20
sensitivity and cisplatin resistance, as well as to assess
ASS1 regulation in response to cisplatin and in com-
bination with ADI-PEG 20 in HCC. Utilizing several hu-
man HCC cell lines with varying amounts of ASS1, we
report that ASS1 silencing confers sensitivity to ADI-
PEG 20 and resistance to cisplatin. A good correlation is
also observed between the methylation status of the
ASS1 promoter, sensitivity to ADI-PEG 20 and resis-
tance to cisplatin. In addition, cisplatin treatment down-
regulates ASS1 protein expression in select HCC cell
lines. Finally, the expression level of ASS1 during com-
bination drug treatments with ADI-PEG 20 and cisplatin
is cell line and concentration-dependent, but is predo-
minantly dictated by ADI-PEG 20 at more clinically rele-
vant concentrations. Taken together, our data indicate
that ADI-PEG 20 and cisplatin will complement each
other in a clinically relevant heterogeneous tumor, thus
providing a rationale for combining these two drugs for
the treatment of HCC.
Methods
Cell culture
The following human HCC cell lines were obtained from
Dr. Yuh-Shan Jou at the Institute of Biomedical Sciences,
Academia Sinica, Taipei, Taiwan: Sk-Hep1, Huh7, Tong,
HCC36, Hep3B, Malhavu, PLC5 and Huh6. The human
HCC cell lines HepG2, SNU398 and SNU182 were from
American Type Culture Collection (ATCC, Manassas,
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tive) derived from a patient prior to treatment and
A2780CR is a cisplatin-resistant cell line that was deve-
loped by exposure of the parent A2780 cell line to increa-
sing concentrations of cisplatin. Both A2780 and
A2780CR cell lines were obtained from Sigma-Aldrich
(St. Louis, MO). The following cells were grown in
Dulbecco’s Modified Eagle Medium (DMEM) (Lonza,
Allendale, NJ) containing 10% heat-inactivated fetal
bovine serum (FBS; Life Technologies, Carlsbad, CA),
1% L-glutamine (Life Technologies) and 1% non-essential
amino acids (NEAA, Life Technologies): Sk-Hep1, Huh7,
Tong, HCC36, Hep3B, Malhavu, PLC5, Huh6 and HepG2.
SNU398, SNU182 and the ovarian cell lines were main-
tained in RPMI 1640 (Lonza) with 10% heat-inactivated
FBS and 1% L-glutamine. All cells were sub-cultured two
times a week using trypsin/EDTA (Life Technologies) and
were grown at 37°C in 5% CO2.
Cell viability assay
Cell viability (IC50) values for ADI-PEG 20 and cisplatin
(Sigma-Aldrich) were determined using the CellTiter-Glo
(CTG) luminescent cell viability assay (Promega, Madison,
WI). Cells (3,000-6,000 cells/well) were plated in 100 μL
medium/well in 96-well black micro-clear plates (Greiner
bio-one, Monroe, NC). Following overnight incubation at
37°C and 5% CO2, cells were exposed to a range of drug
concentrations from a 50X plate (2 μL/well). Each concen-
tration of drug was added to duplicate wells. After 72 h in-
cubation, 25 μL/well of CTG reagent was added directly
to the medium and the plates were shaken for 5 min,
resulting in cell lysis and the generation of a luminescent
signal proportional to the amount of ATP present. The
luminescence values were read on a SpectraMax M3
microplate reader (Molecular Devices, Sunnyvale, CA)
and converted to a percent cell viability that was calcu-
lated relative to the viability in corresponding matched
DMSO-treated cells, which was designated as 100% viable.
IC50 values (concentration of drug that results in 50% of
luminescence signal compared with the DMSO-treated
control) were obtained from nonlinear regression analysis
of concentration-effect curves using GraphPad Prism ver-
sion 6.0 software (San Diego, CA).
Immunoblot analysis
Whole-cell extracts were made from 90% confluent cul-
tures of all human cells. Cells were lysed in RIPA buffer
(Sigma-Aldrich), with added protease inhibitor cocktail
(Roche Molecular Systems, Pleasanton, CA) and PMSF
(Sigma-Aldrich). Total lysate protein was quantified using
a Coomassie Plus (Bradford) Protein Assay Reagent
(Pierce, Rockford, IL). Cell extracts (20 μg) were run on
NuPage 4-12% Bis-Tris Gels (Life Technologies) and then
transferred to PVDF membranes (Life Technologies). Themembranes were blocked in TBST buffer (Tris-HCL, 0.1%
Tween) containing 5% Blotting-Grade Blocker (Bio-Rad,
Hercules, CA) for 2 h at room temperature and then
probed using a mouse monoclonal antibody to ASS1
(Polaris Pharmaceuticals, in-house) at a dilution of 1:500.
GAPDH was used as a loading control for each western
blot, so the membranes were cut and also probed with a
rabbit polyclonal antibody to GAPDH (Millipore, Billerica,
MA) at a dilution of 1:10,000. The blots were incubated
with both primary antibodies overnight at 4°C on a rocker.
After washing with TBST buffer, the membranes were incu-
bated with secondary antibodies: goat anti-mouse for ASS1
(Santa Cruz Biotechnology, Dallas, TX) (1:10,000) and goat
anti-rabbit for GAPDH (Santa Cruz Biotechnology)
(1:60,000) and incubated at room temperature for 1 h. The
secondary antibodies were detected using either the Super-
Signal West Pico (GAPDH) or Femto (ASS1) Chemilu-
minescent Substrate (Pierce) and blots were read on a
Bio-Rad ChemiDox XRS + System. ASS1 and GAPDH
levels were quantified using Image Lab Software (Bio-Rad,
Hercules, CA).
For ASS1 protein determination after cisplatin treat-
ments or for ADI-PEG 20 and cisplatin combination ana-
lysis, the same procedure was used with the following
modifications. Cells were plated in two identical 96-well
plates: one for cell viability and/or normalization for cell
numbers between wells (luminescence assay; see Methods
above) and one for lysis (ASS1 detection). After 72 h drug
treatments, lysates were made and probed for protein
analysis. For ASS1 and GAPDH detection, media was re-
moved and each well of the microplate was washed with
100 μL of PBS buffer (Gibco by Life Technologies).
NuPage LDS sample buffer (30 μL of 1x sample buffer,
Life Technologies) containing 50 mM DTT was then
added to each well and the plate was wrapped in parafilm
and frozen at -80°C for at least one hour to ensure lysis.
After lysis, the samples in each well were spun and then
used for immunoblot analysis. To account for the different
number of viable cells in each well of the microplate,
samples were normalized using the relative luminescence
values for each corresponding well of the identical
microplate.
Bisulfite modification and methylation-specific PCR
The EZ DNA Methylation-Direct Kit (Zymo Research
Corporation, Irvine, CA) was used to perform complete
DNA bisulfite conversion directly from the human cell
lines. This process converts unmethylated cytosine resi-
dues to uracil while methylated cytosine residues remain
unchanged. In general, 10,000-40,000 cells (~60-250 ng
genomic DNA) were used as starting material for each
cell line. Methylation-specific PCR (MSP) of a 188 bp
fragment located between 300 and 500 bp downstream
of the transcription start site (TSS) was then performed
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moter. Bisulfite-modified DNA (150 ng) was used as a
template for PCR reactions with primers specific for
methylated (M) or unmethylated (UM) sequences. Primer
sequences are: (1) M forward: 5′-TTTTTTTCGTTG
TTTATTTTTTAGTC-3′; (2) M reverse: 5′-CTAAAA
TCCGATACCAAACGTT-3′; (3) UM forward: 5′-TTTT
TGTTGTTTATTTTTTAGTTGA-3′ and (4) UM reverse:
5′-AACCTAAAATCCAATACCAAACATT-3′. Primers
were purchased from IDT Technologies (San Diego, CA).
PCR conditions for the methylated primers were as
follows: 8 cycles of 95°C for 2 min, 54.8°C for 30 sec and
72°C for 30 sec were followed by 32 cycles of 95°C for
30 sec, 54.8°C for 30 sec and 72°C for 30 sec, then a final
extension at 72°C for 10 min. The PCR conditions for the
unmethylated primers were identical, except the annealing
temperature was 48°C instead of 54.8°C. The HotStarTaq
d-Tect polymerase (EpiTect MSP kit; Qiagen, Valencia,
CA) was used for the PCR reactions. The PCR samples
were run on 2% pre-cast agarose E-gels (Life Technologies)
containing a fluorescent stain for visualization. The hu-
man methylated and non-methylated DNA set (Zymo
Research) were used as negative and positive controls for
bisulfite conversion efficiency, and MSP was similarly per-
formed using a set of control primers designed to amplify
non-methylated, methylated and mixed methylation copies
of the death-associated protein kinase 1 gene (DAPK1),
with an expected size of 274 bp.
Statistical analysis
GraphPad Prism version 6.0 was used to test results for
statistical significance. Differences in ASS1 levels between
groups were analyzed using an unpaired two-tailed t-test.
A p value < 0.05 was set as a level of statistical signifi-
cance. In determining statistical significance for ASS1 pro-
tein levels after cisplatin treatments or for ADI-PEG 20
and cisplatin combination analysis, each drug concentra-
tion was compared to the untreated, or zero drug, sample
to attain a p value for that particular drug concentration.
Results
ASS1 deficiency confers sensitivity to ADI-PEG 20 and
resistance to cisplatin
To study the relationship between ASS1 expression and
sensitivity to ADI-PEG 20 and cisplatin, we first screened
11 human HCC cell lines for this protein. The western
blot shown in Figure 1A reveals the different amount of
ASS1 protein in select cell lines. The signal intensity of
the bands were quantified and normalized by taking the
level of ASS1 in the HepG2 cell line as 1. For simplicity,
the cell lines were categorized into one of four groups and
are designated as either ASS1-high, medium, low or nega-
tive (Table 1). ASS1 expression allows cells to utilize cit-
rulline as a substrate for arginine synthesis. ASS1-negativeand low lines should thus be sensitive to ADI-PEG 20,
while ASS1-high cell lines should be resistant to this drug.
As expected, the ASS1-negative and low cell lines
Sk-Hep1, SNU398 and Tong are very sensitive to ADI-
PEG 20, with IC50 values around 1 nM (0.05 μg/mL;
Table 1). Cell lines that have some ASS1, designated as
ASS1-medium, are less sensitive to ADI-PEG 20, while
the ASS1-high cell lines are resistant to this drug.
Figure 1B displays ADI-PEG 20 IC50 curves for three
representative HCC cells lines: Sk-Hep1, HepG2 and
Malhavu. As shown, the ADI-PEG 20 curve for the ASS1-
negative Sk-Hep1 cell line is very steep, with only 5-10%
cell viability remaining at the highest concentration of
ADI-PEG 20 (100 nM; 5 μg/mL), while this drug only kills
50% of the ASS1-medium HepG2 cells at the same
concentration. In contrast, the ASS1-high line Malhavu is
completely resistant to ADI-PEG 20.
A reciprocal relationship between ASS1 expression
and platinum resistance has been previously observed in
ovarian cancer [22,36]. Interestingly, the HCC cell lines
also show different sensitivity to cisplatin depending on
the level of ASS1 present in each line. All of our ASS1-
negative or low cell lines are resistant to cisplatin, with
Tong and Sk-Hep1 both having an IC50 value above
30 μM (Table 1). The ASS1-high cell lines are at least 5
to 10-fold more sensitive to cisplatin, with IC50 values in
the low micromolar for most. Figure 1C shows cisplatin
IC50 curves for three representative HCC cells lines: Sk-
Hep1, HepG2 and Malhavu. Surprisingly, this reciprocal
trend between ASS1 expression and cisplatin resistance
that we observe in our HCC cell lines is not seen with
other platinum therapies such as oxaliplatin and car-
boplatin, or other chemotherapies such as doxorubicin,
docetaxel, 5-FU or gemcitabine (data not shown). In
addition, cisplatin IC50 values have been obtained for mul-
tiple cell lines from three other cancer types (colorectal
cancer, melanoma and non-small cell lung cancer) and no
such trend is observed, at least in the cell lines tested (data
not shown). Thus, this reciprocal relationship between
ASS1 expression and cisplatin may be exclusive to HCC
and ovarian cancer. In summary, our data thus far indicate
that ADI-PEG 20 is effective at killing ASS1-negative
HCC cells, while cisplatin is effective at killing ASS1-
positive HCC cells. This observation suggests that their
combination should be an efficacious treatment for het-
erogeneous cell populations that exist in tumors.
Methylation status of the ASS1 promoter correlates with
sensitivity to ADI-PEG 20 and resistance to cisplatin
Epigenetic silencing via promoter CpG methylation in cell
lines lacking ASS1 expression has been demonstrated in
multiple cancer types [4,22-24,26,27]. A strong correlation
between the methylation of the ASS1 promoter and sensi-
tivity to ADI-PEG 20 has been established in these various
Figure 1 Effect of ASS1 expression on the sensitivity of HCC cell lines to ADI-PEG 20 and cisplatin treatment. (A) ASS1 protein levels
from cell lysates were determined by western blot. GAPDH was run as a loading control. The signal intensities of the bands were quantified and
normalized by taking the level of HepG2 cells as 1. (B and C) Sensitivity of three representative HCC cell lines to ADI-PEG 20 and cisplatin. Cells
were cultured in medium containing various concentrations of (B) ADI-PEG 20 and (C) cisplatin. Duplicate samples were assessed for cell viability
after 72 h using the Promega luminescence assay. Percent cell viability from either ADI-PEG 20 or cisplatin-treated cells was calculated relative
to the viability in corresponding matched DMSO-treated cells, which was designated as 100%. The data are representative of three or more
independent experiments. Error bars represent S.D.
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in regulating platinum sensitivity via DNA methylation-
dependent epigenetic regulation of the ASS1 promoter
has been observed in ovarian cancer [22]. This study dem-
onstrated the presence of methylated CpG dinucleotides
in the ASS1 promoter of a cisplatin resistant A2780CR
cell line, while the parental A2780 line was essentially
unmethylated. Using the A2780 and A2780CR ovarian cell
lines as controls, we show the ASS1 DNA in the A2780
cell line is entirely unmethylated, while it is almost com-
pletely methylated in the A2780CR cell line (Figure 2A).
To determine if our ASS1-negative HCC cisplatin-resis-
tant cell lines are epigenetically regulated, we examined
the methylation status of the ASS1 promoter in the
Sk-Hep1 and SNU398 cell lines. As expected, both of
these cisplatin-resistant, ASS1-deficient cell lines are
completely methylated at the ASS1 promoter (Figure 2B),
confirming that the silencing of ASS1 in these HCC cell
lines is indeed epigenetic-based. In addition, Sk-Hep1
and SNU398 are very sensitive to arginine deprivation,demonstrating that methylation of the ASS1 promoter
also correlates with sensitivity to ADI-PEG 20 in HCC.
Furthermore, all of our ASS1-positive HCC cell lines are
unmethylated (Figure 2C), display sensitivity to cisplatin,
and are increasingly resistant to ADI-PEG 20. Surpris-
ingly, the ASS1 promoter is entirely unmethylated in the
Tong cell line (Figure 2B), even though these cells contain
very little ASS1 protein, are resistant to cisplatin and sen-
sitive to ADI-PEG 20 (Table 1 and Figure 1A). Overall, in
HCC, we observe a good association between the methy-
lation status of the ASS1 promoter, ADI-PEG 20 sensiti-
vity and cisplatin resistance in six out of the seven cell
lines tested.
Cisplatin treatment down-regulates ASS1 in ASS1-positive
HCC cell lines
We have previously demonstrated a reciprocal relation-
ship between ASS1 expression and cisplatin resistance in
our HCC cell lines. Therefore, we next investigated
whether treatment with cisplatin could down-regulate










Huh7 High > 10a 2.7 ± 0.3
Malhavu High No curve 3.3 ± 0.2
Huh6 High No curve 2.9 ± 0.8
SNU182 High No curve 1.3 ± 0.3
Hep3B High > 10a 0.36 ± 0.02
PLC5 High No curve 2.2 ± 0.3
HCC36 Medium 2.4 ± 0.3 2.9 ± 1.2
HepG2 Medium 1.4 ± 0.2 4.7 ± 0.4
Tong Low 1.3 ± 0.1 >30b
Sk-Hep1 Negative 1.1 ± 0.1 >30b
SNU398 Negative 1.2 ± 0.1 23 ± 7.8
HCC cells were treated with various concentrations of either ADI-PEG 20 or
cisplatin and the Promega luminescence assay was performed. IC50 was
calculated on replicates (n = 3 to 4, mean ± SD).
aNo good IC50 fit: approximately 25-30% loss of cell viability by 10 nM
ADI-PEG 20.
bNo good IC50 fit: lower limit.
Figure 2 Methylation status of the ASS1 promoter in HCC cancer cell
and MSP was subsequently carried out to determine the methylation statu
methylated. Unmethylated and methylated controls (UC and MC) were inc
as follows: ASS1: 188 bp; control DNA: 274 bp. Data is representative of 3-4
A2780CR. (B) ASS1-negative/low cells: SNU398, Sk-Hep1 and Tong. (C) ASS1
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positive HCC cell lines: HepG2, HCC36 and SNU182.
Cells were treated in 96-well microplates with increasing
cisplatin concentrations for 72 h, and luminescence
values, indicative of cell viability, were then used to load
similar amounts of protein across all of the cisplatin-
treated wells. ASS1 protein expression was subsequently
determined by immunoblot analysis and normalized to
GAPDH protein at each cisplatin concentration. Figure 3
(A and B) shows that ASS1 protein expression is pro-
gressively reduced in both the HepG2 and HCC36 cell
lines as the cisplatin concentration is increased. The
IC50 values for cisplatin in the HepG2 and HCC36 cell
lines are 4.7 μM and is 2.9 μM, respectively. Thus, the
ASS1 levels drop by approximately 50% relative to zero
drug at this concentration of cisplatin in the HepG2 cell
line and 40% in the HCC36 cells (Figure 3A and B). Fur-
ther increasing the cisplatin results in even less ASS1 ex-
pression, with approximately 70% down-regulation of
ASS1 by 30 μM cisplatin in HepG2 cells (Figure 3A).
We also studied the ASS1 expression level with cisplatin
in the SNU182 cell line, which has the lowest IC50 value
for cisplatin (1.3 μM) of the three cell lines we chose to
investigate. Because cisplatin is more potent in this cell
line than the others, there is significant cell death at thelines. DNA bisulfite conversion was performed directly from the cells
s of the ASS1 promoter. UM denotes unmethylated and M denotes
luded to assess bisulfite conversion efficiency. Expected band sizes are
independent experiments. (A) Control: ovarian cell lines A2780 and
-positive cells: HCC36, SNU182, Malhavu and HepG2.
Figure 3 Cisplatin treatment down-regulates ASS1 protein in HCC cell lines. Cells were treated with indicated cisplatin concentrations in
identical rows of a 96-well microplate. After 72 h, triplicate samples were assessed for cell viability by reading the luminescence and lysates were
made out of the remaining identical rows. Luminescence values were used to load equal amounts of protein and ASS1 expression was assessed
by western blot. ASS1 levels were normalized to GAPDH at each cisplatin concentration and expressed relative to zero drug (100%). The data
are representative of three to four independent experiments. Error bars represent S.D. An unpaired t-test was conducted to determine the
significance of the change in ASS1 protein levels after each cisplatin concentration treatment as compared to the untreated, or zero drug
sample (*p < 0.05, **p < 0.005, ***p < 0.001, ****p < 0.0001). (A) HepG2 cells. (B) HCC36 cells. (C) SNU182 cells.
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ging to use luminescence values to compare the total
ASS1 and GAPDH protein at both 15 μM and 30 μM
cisplatin with that in the lower concentration wells. For
this reason, we have only quantified ASS1 to a concen-
tration of 7.5 μM in the SNU182 cell line (Figure 3C).
As with the HepG2 and HCC36 cell lines, we do see a
reduction of ASS1 expression in the SNU182 cell line
with increasing cisplatin; however, the drop in ASS1
levels is not as gradual. The ASS1 expression decreases
by approximately 50% relative to zero drug around the
IC50 concentration of cisplatin. Taken together, our data
indicate that cisplatin treatment reduces ASS1 protein
expression in three HCC cell lines. Interestingly, we de-
tect primarily unmethylated DNA at the ASS1 promoter
for all three cell lines after the 72 h cisplatin treatment
(data not shown), suggesting the mechanism of cisplatindown-regulation during these acute drug treatments is
not epigenetic-based.
ASS1 expression level during ADI-PEG 20 and cisplatin
combination treatment is predominantly dictated by
ADI-PEG 20
The data thus far demonstrate a correlation between low
ASS1 expression, resistance to cisplatin and sensitivity to
ADI-PEG 20. Such a relationship provides a situation
where one drug drives efficacy in an ASS1-negative cell
line (ADI-PEG 20) and the other drives efficacy in an
ASS1-high cell line (cisplatin), suggesting a favorable
combination drug treatment. Our results demonstrate
that cisplatin down-regulates ASS1 in three represen-
tative HCC cell lines. Thus, we wanted to determine the
effect of the addition of ADI-PEG 20 to cisplatin on
the ASS1 levels in these same cell lines. To determine
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ment, cells were simultaneously treated with cisplatin
and ADI-PEG 20 in the same wells of a microplate, and
then analyzed for ASS1 protein expression. Two concen-
trations of cisplatin that are known to reduce the ASS1
protein expression were chosen (5 μM and 7.5 μM)
and increasing concentrations of ADI-PEG 20 wereFigure 4 ASS1 expression during cisplatin and ADI-PEG 20 combinati
cisplatin concentration of either 5 μM or 7.5 μM and increasing concentrat
triplicate samples were assessed for cell viability by reading the luminescen
Luminescence values were used to load equal amounts of protein and ASS
to GAPDH at each treatment condition and expressed relative to zero drug
experiments. Error bars represent S.D. An unpaired t-test was conducted to
each cisplatin and ADI-PEG 20 combination treatment as compared to the
****p < 0.0001). (A) HepG2 cells. (B) HCC36 cells. (C) SNU182 cells.simultaneously added to the same wells. As expected,
for HepG2 cells, treatment at both cisplatin concentra-
tions alone causes a decline in ASS1 protein levels by
approximately 50%, which agrees with our previous re-
sults (Figure 3A). Figure 4A shows that as ADI-PEG 20
is added to cisplatin at both concentrations, the ASS1
levels increase. At both concentrations of cisplatin andon treatment in HCC cells. Cells were simultaneously treated with a
ions of ADI-PEG 20: 0.5, 1, 2, 4 and 8 nM in the same well. After 72 h,
ce and lysates were made out of the remaining identical rows.
1 levels were assessed by western blot. ASS1 levels were normalized
(100%). The data are representative of two to three independent
determine the significance of the change in ASS1 protein levels after
untreated, or zero drug sample (*p < 0.05, **p < 0.005, ***p < 0.001,
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almost completely restored to that observed without
drug treatment. For the HepG2 cell line, our results in-
dicate that, in combination, ASS1 levels will be dictated
by the ADI-PEG 20 at a cisplatin concentration around
its IC50 value. The same experiment was performed with
the HCC36 cell line and we observe a similar trend
(Figure 4B). In agreement with previous results, treat-
ment at both 5 μM and 7.5 μM cisplatin alone results in
significant down-regulation of ASS1. At both concentra-
tions of cisplatin, ASS1 levels do increase upon addition
of ADI-PEG 20, but not to the same extent observed in
the HepG2 cell line. We also performed this experiment
at 2 μM cisplatin, which is closer to the IC50 value for
cisplatin in HCC36 cells, and detect a complete return
of ASS1 at both 4 and 8 nM ADI-PEG 20 (data not
shown). Thus, for the HCC36 cell line, the ASS1 levels
will also be determined by the ADI-PEG 20 at a cisplatin
concentration around its IC50 value.
The last cell line we investigated was SNU182, and
surprisingly, we observe a different outcome. At both cis-
platin concentrations, the ASS1 levels do not return, even
at the highest concentration of ADI-PEG 20 (Figure 4C).
The data suggest that in this cell line, ADI-PEG 20
addition is not sufficient to overcome the ASS1 down-
regulation induced by cisplatin. One possible explanation
is that the SNU182 cell line does have a slightly lower IC50
value for cisplatin than the other 2 cell lines (Table 1).
Thus, we examined the ASS1 levels in the SNU182 cell
line at 2 μM cisplatin, which is closer to its IC50 value of
1.3 μM. At 2 μM cisplatin alone, we see 50% down-
regulation of ASS1. Interestingly, as ADI-PEG 20 is added,
we do not observe any increase in ASS1 expression
(data not shown), indicating that cisplatin will dictate
ASS1 levels.
Discussion
The future for the treatment of arginine auxotrophic can-
cers lies in combination therapies. Several ADI-PEG 20
and cisplatin combination trials are planned. Therefore,
understanding the correlation between ASS1 expression
and cisplatin and ADI-PEG 20 sensitivities, as well as how
ASS1 is regulated by both drugs could provide valuable
information for trial design. For the first time, we have
shown that there is a reciprocal relationship between
ASS1 expression and cisplatin resistance in several human
HCC cell lines. We have observed that resistance is spe-
cific to cisplatin, as sensitivity to other platinums and che-
motherapeutic agents are unaffected by ASS1 expression.
In addition, methylation of the ASS1 promoter does asso-
ciate with sensitivity to ADI-PEG 20, and in HCC, also
corresponds with cisplatin resistance, as previously de-
monstrated in ovarian cancer [22]. These findings suggest
that the methylation status of the ASS1 promoter intumors may predict sensitivity to arginine deprivation
with ADI-PEG 20 and also support the future prospect of
using methylation profiling to identify which HCC pa-
tients may benefit from either cisplatin or ADI-PEG 20.
Our novel data also indicate that cisplatin down-
regulates ASS1 protein expression in three HCC cell lines.
How exactly cisplatin is affecting ASS1 levels during these
acute treatments is currently unknown. Previously pub-
lished studies indicate that ASS1 regulation occurs at the
transcriptional level [37-40]. For example, it has been
demonstrated that glutamine stimulated ASS1 expression
in Caco-2 cells through O-glycosylation of the transcrip-
tion factor Sp1 [40], while expression of the ASS1 gene
has been shown to be stimulated by interleukin-1β in
Caco-2 cells through activation of the transcription factor
nuclear factor-ĸβ [38]. In melanoma cells, hypoxia-
inducible factor (HIF-1α)-mediated transcriptional repres-
sion of ASS1 has been observed [31,33]. Other factors
have been shown to positively or negatively regulate ASS1
expression. For example, cAMP increases ASS1 expression,
while fatty acids cause suppression of this protein [41,42],
and factors such as hormones and pro-inflammatory sti-
muli are also known to regulate ASS1 expression [39,43].
Interestingly, there is suggestion that acquired re-
sistance to cytotoxic agents occurs predominantly via
epigenetic events [44,45]. A significant function for
ASS1 in regulating platinum sensitivity via methylation
of the ASS1 promoter has been observed in ovarian can-
cer utilizing the A2780 and A2780CR cell lines [22]. The
A2780CR cell line was established by intermittent expo-
sure of the parental A2780 cell line to stepwise, increa-
sing concentrations of cisplatin up to a concentration of
8 μM over a period of approximately 9 months [46].
This cell line was found to be 7.3-fold more resistant
than the parental line, and it was indicated that this de-
gree of resistance in the A2780CR cell line was stable for
at least nine months during subculture in drug-free
medium. Our experience with a commercially available
A2780CR cell line is similar. We have observed that
A2780CR does not express ASS1, is 12-fold more resis-
tant to cisplatin than the parental cell line, and is com-
pletely methylated at the ASS1 promoter after being
subcultured in cisplatin-free medium for 2 months.
Given the similarities to ovarian cancer that we have
observed in our HCC cell lines regarding ASS1 expres-
sion, methylation status of the ASS1 promoter and cis-
platin resistance, we are currently establishing a HepG2
cisplatin-resistant (HepG2CR) cell line by progressively
exposing HepG2 cells to increasing cisplatin. Preliminary
data indicate a three-fold IC50 value increase for cis-
platin in HepG2CR over the parental cell line after only
one month of drug exposure. Once we acquire a more
permanent resistant phenotype, we will determine the
methylation status of HepG2CR and perform other
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platin resistance in HCC.
Several ADI-PEG 20 combination trials are ongoing
or planned, including a combination with cisplatin for
metastatic melanoma, ovarian cancer and other solid tu-
mors, docetaxel for prostate and non-small cell lung
cancer (NSCLC), doxorubicin for breast cancer, and cis-
platin and pemetrexed for NSCLC and malignant pleural
mesothelioma [20]. We have determined that ASS1 loss
is a biomarker of cisplatin resistance and ADI-PEG 20
sensitivity, whereas ASS1 positivity is an indicator of
cisplatin sensitivity and ADI-PEG 20 resistance in HCC
cell lines. This observation suggests that a cisplatin and
ADI-PEG 20 regimen should be superior to either drug
alone for the treatment of HCC patients. To examine
the potential for the use of ASS1 as a predictor in com-
bination therapy, we sought to determine the ASS1
levels in HCC cells with both drugs present. Predictably,
we found that the ASS1 protein levels will be dictated by
one of the two drugs and is concentration-and cell-line
dependent. In two of the three cell lines tested, the
ASS1 levels seemed to be controlled by ADI-PEG 20,
while cisplatin was able to maintain low ASS1 levels in
the remaining cell line. Obviously, it is hard to predict
clinical behavior from cell-based assays. We believe that
ADI-PEG 20 will influence the ASS1 level of this two-
drug regimen at more clinically relevant concentrations,
resulting in higher ASS1 levels. This observation sug-
gests that long term treatment with this combination
could result in cisplatin resistant cells becoming cisplatin
sensitive. Furthermore, several groups have observed
that reduced expression of ASS1 is significantly associ-
ated with advanced tumor stage and an association with
a worse clinical outcome [21-25]. These observations
imply that the higher ASS1 levels present with the
addition of ADI-PEG 20 to cisplatin may elicit better
clinical outcomes for HCC patients. Extending these
observations further to the clinic, our results suggest that
while ASS1 may be a predictive biomarker for either
ADI-PEG 20 or cisplatin as a single agent or pre-therapy,
the status of this indicator may change by addition of the
second drug and possibly evolve during tumor progression
or metastasis. This concept of intratumoral heterogeneity
within the same patient is growing in recognition and
discordance of predictive or prognostic biomarker testing
results between primary tumor and metastases or re-
sistance acquisition has been reported in several tumor
types [47].
Conclusion
Our data support the rationale of combining cisplatin
and ADI-PEG 20 in the clinical treatment of HCC. We
believe these two drugs will be complementary in a cli-
nically relevant heterogeneous tumor. Furthermore, inHCC, sensitivity to ADI-PEG 20 may be superior in
cases that have relapsed after cisplatin-based chemo-
therapy. Extending beyond HCC to other cancers, our
results suggest that in the combination setting, a patient
does not necessarily need to have an ASS1-deficient
tumor to reap benefit from an ADI-PEG 20 and cisplatin
drug treatment.
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